Annarica Calcabrini

Dr. Annarica Calcabrini

Italian National Institute of Health (ISS), Rome, Italy
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2020 in Molecules
Verified
Journal Article
Open access
PDF file
Marisa ColoneMarisa Colone
Marisa Colone
ACAnnarica Calcabrini
Annarica Calcabrini
Annarita StringaroAnnarita Stringaro
Annarita Stringaro
In recent decades, increasing interest in the use of natural products in anticancer therapy field has been observed, mainly due to unsolved drug-resistance problems. The antitumoral effect of natural compounds involving different signaling pathways and cellular mechanisms has been largely demonstrated in in vitro and in vivo studies. The encapsulation of natural products into different delivery systems may lead to a significant enhancement of their anticancer efficacy by increasing in vivo stability and bioavailability, reducing side adverse effects and improving target-specific activity. This review will focus on research studies related to nanostructured systems containing natural compounds for new drug delivery tools in anticancer therapies.

9 August 2024 in Molecules
Verified
Journal Article
Open access
PDF file
GBGiuseppina Bozzuto
Giuseppina Bozzuto
ACAnnarica Calcabrini
Annarica Calcabrini
Marisa ColoneMarisa Colone
Marisa Colone
Maria CondelloMaria Condello
Maria Condello
MDMaria Luisa Dupuis
Maria Luisa Dupuis
Annarita StringaroAnnarita Stringaro
Annarita Stringaro
Cancer is a complex disease that affects millions of people and remains a major public health problem worldwide. Conventional cancer treatments, including surgery, chemotherapy, immunotherapy, and radiotherapy, have limited achievements and multiple drawbacks, among which are healthy tissue damage and multidrug-resistant phenotype onset. Increasing evidence shows that many plants’ natural products, as well as their bioactive compounds, have promising anticancer activity and exhibit minimal toxicity compared to conventional anticancer drugs. However, their widespread use in cancer therapy is severely restricted by limitations in terms of their water solubility, absorption, lack of stability, bioavailability, and selective targeting. The use of nanoformulations for plants’ natural product transportation and delivery could be helpful in overcoming these limitations, thus enhancing their therapeutic efficacy and providing the basis for improved anticancer treatment strategies. The present review is aimed at providing an update on some phytocompounds (curcumin, resveratrol, quercetin, and cannabinoids, among others) and their main nanoformulations showing antitumor activities, both in vitro and in vivo, against such different human cancer types as breast and colorectal cancer, lymphomas, malignant melanoma, glioblastoma multiforme, and osteosarcoma. The intracellular pathways underlying phytocompound anticancer activity and the main advantages of nanoformulation employment are also examined. Finally, this review critically analyzes the research gaps and limitations causing the limited success of phytocompounds’ and nanoformulations’ clinical translation.

21 June 2023 in Nanoscale Advances
Verified
Journal Article
Open access
PDF file
SASimone Amatori
Simone Amatori
ALAlberto Lopez
Alberto Lopez
Carlo MeneghiniCarlo Meneghini
Carlo Meneghini
ACAnnarica Calcabrini
Annarica Calcabrini
Marisa ColoneMarisa Colone
Marisa Colone
CBChiara Battocchio
Chiara Battocchio
Gold nanorod derivatization with CTAB and hydroquinone (HQ) or ascorbic acid (AA) allows the preparation of on-demand functionalized nanomaterials of appropriate shape and size.

29 March 2011 in JBIC Journal of Biological Inorganic Chemistry
Verified
Journal Article
Closed access
PDF file
Lisa Dalla ViaLisa Dalla Via
Lisa Dalla Via
Saverio SantiSaverio Santi
Saverio Santi
Vito Di NotoVito Di Noto
Vito Di Noto
AVAlfonso Venzo
Alfonso Venzo
EAENZO AGOSTINELLI
ENZO AGOSTINELLI
ATAntonio Toninello
Antonio Toninello

26 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
VMVíctor Mayoral-Varo
Víctor Mayoral-Varo
MSMaría Pilar Sánchez-Bailón
María Pilar Sánchez-Bailón
ACAnnarica Calcabrini
Annarica Calcabrini
MGMarta García-Hernández
Marta García-Hernández
VFValerio Frezza
Valerio Frezza
Jorge Martín-PérezJorge Martín-Pérez
Jorge Martín-Pérez
The role of Src family kinases (SFKs) in human tumors has been always associated with tyrosine kinase activity and much less attention has been given to the SH2 and SH3 adapter domains. Here, we studied the role of the c-Src-SH2 domain in triple-negative breast cancer (TNBC). To this end, SUM159PT and MDA-MB-231 human cell lines were employed as model systems. These cells conditionally expressed, under tetracycline control (Tet-On system), a c-Src variant with point-inactivating mutation of the SH2 adapter domain (R175L). The expression of this mutant reduced the self-renewal capability of the enriched population of breast cancer stem cells (BCSCs), demonstrating the importance of the SH2 adapter domain of c-Src in the mammary gland carcinogenesis. In addition, the analysis of anchorage-independent growth, proliferation, migration, and invasiveness, all processes associated with tumorigenesis, showed that the SH2 domain of c-Src plays a very relevant role in their regulation. Furthermore, the transfection of two different aptamers directed to SH2-c-Src in both SUM159PT and MDA-MB-231 cells induced inhibition of their proliferation, migration, and invasiveness, strengthening the hypothesis that this domain is highly involved in TNBC tumorigenesis. Therefore, the SH2 domain of c-Src could be a promising therapeutic target and combined treatments with inhibitors of c-Src kinase enzymatic activity may represent a new therapeutic strategy for patients with TNBC, whose prognosis is currently very negative.

19 July 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Annarita StringaroAnnarita Stringaro
Annarita Stringaro
Stefano SerraStefano Serra
Stefano Serra
AGAlessandro Gori
Alessandro Gori
ACAnnarica Calcabrini
Annarica Calcabrini
Marisa ColoneMarisa Colone
Marisa Colone
Alberto VitaliAlberto Vitali
Alberto Vitali
Breast cancer is one of the most diffuse cancers in the world and despite the availability of the different drugs employed against it, the need for new and particularly more specific molecules is ever growing. In this framework, natural products are increasingly assuming an important role as new anticancer drugs. Aloe-emodin (AE) is one of the best characterized molecules in this field. The functionalization of bioactive natural products with selected peptide sequences to enhance their bioavailability and specificity of action is a powerful and promising strategy. In this study, we analyzed the cell specificity, cell viability effects, intracellular distribution, and immune cell response of a new peptide conjugate of Aloe-emodin in SKBR3 and A549 cell lines by means of viability tests, flow cytometry, and confocal microscopy. The conjugate proved to be more effective at reducing cell viability than AE in both cell lines. Furthermore, the results showed that it was mainly internalized within the SKBR3 cells, showing a nuclear localization, while A459 cells displayed mainly a cytoplasmic distribution. A preserving effect of the conjugate on NKs’ cell function was also observed. The designed conjugate showed a promising specific activity towards HER2-expressing cells coupled with an enhanced water solubility and a higher cytotoxicity; thus, the resulting proof-of-concept molecule can be further improved as an anticancer compound.